title: Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic Activity.
abstract: This Letter describes the discovery, SAR and in vitro and in vivo pharmacological profile of a novel non-MPEP derived mGlu(5) positive allosteric modulator (PAM) based upon an N-aryl piperazine chemotype. This mGlu(5) chemotype exhibits the ability to act as either a non-competitive antagonist/negative allosteric modulator (NAM) or potentiator of the glutamate response depending on the identity of the amide substituent, i.e., a 'molecular switch'. A rapidly optimized PAM, 10e (VU0364289), was shown to be potent and specific for the rat mGlu(5) receptor and subsequently demonstrated to be efficacious in a clinically relevant rodent model predictive of anti-psychotic activity, thus providing the first example of a centrally active mGluR(5) PAM optimized from an HTS-derived mGluR5 competitive antagonist.
authors: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232-6600, USA ; Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-6600, USA.
authors: Ya
authors: Y
authors: Zhou
authors: Jason T
authors: JT
authors: Manka
authors: Alice L
authors: AL
authors: Rodriguez
authors: C David
authors: CD
authors: Weaver
authors: Emily L
authors: EL
authors: Days
authors: Paige N
authors: PN
authors: Vinson
authors: Satyawan
authors: S
authors: Jadhav
authors: Elizabeth J
authors: EJ
authors: Hermann
authors: Carrie K
authors: CK
authors: Jones
authors: P Jeffrey
authors: PJ
authors: Conn
authors: Craig W
authors: CW
authors: Lindsley
authors: Shaun R
authors: SR
authors: Stauffer